This is a class action lawsuit over thyroid tablets manufactured and distributed by Westminster Pharmaceuticals, LLC (“Westminster”) and sold through and by CVS Pharmacy, Inc. (“CVS”).
Specifically, the lawsuit pertains to Defendants Westminster’s manufacturing and distribution of adulterated generic prescription thyroid medications containing Levothyroxine and Liothyronine tablets for oral use, branded as “Thyroid Tablets, USP” or “Thyroid Tablets” (hereafter, “Thyroid Tablets”). CVS sold these adulterated generic prescription medications to Plaintiff and other similarly situated consumers.
Levothyroxine (tetraiodothyronine sodium) and Liothyronine (liothyronine sodium) are generic prescription medications indicated as replacement or supplemental therapy in patients with hypothyroidism, among other conditions. Westminster combines both compounds into a generic formulation consisting of a single oral tablet, which is branded as “Thyroid Tablets, USP” or “Thyroid Tablets.” However, due to manufacturing defects originating from overseas laboratories in China, Westminster’s formulation has become adulterated.
On August 9, 2018, the U.S. Food & Drug Administration (“FDA”) posted a notice of a voluntary recall of Thyroid Tablets by Westminster subsequent to multiple violations of the Food Drug and Cosmetics and good manufacturing practices issued there under.
As alleged, Plaintiff and the Class were injured by paying the full purchase price of their Thyroid Tablets. These medications are worthless, as they have been found to be adulterated and are not fit for human consumption.